共 50 条
- [21] Long-Term Safety and Efficacy of Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from the CLEAR Harmony Open-Label Extension Study)AMERICAN JOURNAL OF CARDIOLOGY, 2022, 174 : 1 - 11Ballantyne, Christie M.Banach, MaciejBays, Harold E.Catapano, Alberico L.Laufs, UlrichStroes, Erik S. G.Robinson, PaulaLei, LeiRay, Kausik K.
- [22] PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study (vol 14, pg 322, 2020)JOURNAL OF CLINICAL LIPIDOLOGY, 2020, 14 (05) : 741 - 741Daniels, StephenCaprio, SoniaChaudhari, UmeshManvelian, GarenBaccara-Dinet, Marie T.Brunet, AurelieScemama, MichelLoizeau, VirginieBruckert, Eric
- [23] EFFICACY AND SAFETY OF ALIROCUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDYJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1958 - 1958Gaudet, DanielLopez-Sendon, Jose LuisAverna, MaurizioBigot, GregoryBanach, MaciejLetierce, AlexiaLoy, MeganSamuel, RitaBatsu, IsabelaHenry, Patrick
- [24] PATISIRAN PH 2 OPEN-LABEL EXTENSION STUDY IN FAMILIAL AMYLOIDOTIC POLYNEUROPATHYJOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (12):Schmidt, HartmutAdams, DavidCoelho, TeresaConceicao, IsabelWaddington-Cruz, MarciaBuades, JuanCampistol, JosepPouget, JeanGollob, JaredSuhr, Ole
- [25] Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)AMERICAN JOURNAL OF CARDIOLOGY, 2018, 121 (08): : 940 - 948McCullough, Peter A.Ballantyne, Christie M.Sanganalmath, Santosh K.Langslet, GisleBaum, Seth J.Shah, Prediman K.Koren, AndrewMandel, JonasDavidson, Michael H.
- [26] Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatmentEUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (03) : 302 - 310Santos, Raul D.Ruzza, AndreaWang, BeiMaruff, PaulSchembri, AdrianBhatia, Ajay K.Mach, FrancoisBergeron, JeanGaudet, IsabelleSt Pierre, JulieKastelein, John J. P.Hovingh, G. KeesWiegman, AlbertGaudet, DanielRaal, Frederick J.
- [27] Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension StudyCIRCULATION, 2018, 138Krempf, MichelHopkins, Paul N.Bruckert, EricLuc, GeraldLee, ShaneDonahue, Stephen
- [28] GENOTYPE AND FUNCTION IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA: A SUBANALYSIS FROM THE ELIPSE OPEN-LABEL EXTENSION STUDYATHEROSCLEROSIS, 2024, 395Gaudet, DanielGreber-Platzer, SusanneReeskamp, LaurensIannuzzo, GabriellaRosenson, RobertSahed, SamirStefanutti, ClaudiaStroes, ErikBruckert, EricWaldron, AlpanaBanerjee, PoulabiGeorge, RichardJones, RichardRaal, Frederick J.
- [29] Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trialsINTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 223 : 750 - 757Farnier, MichelGaudet, DanielValcheva, VelichkaMinini, PascalMiller, KathrynCariou, Bertrand
- [30] Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial (vol 80, pg 1980, 2016)CIRCULATION JOURNAL, 2016, 80 (11) : 2414 - 2414Teramoto, TamioKobayashi, MasahikoTasaki, HiromiYagyu, HiroakiHigashikata, ToshinoriTakagi, YoshiharuUno, KiyokoBaccara-Dinet, Marie T.Nohara, Atsushi